Opinion

Video

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.